<DOC>
	<DOCNO>NCT02240017</DOCNO>
	<brief_summary>This phase II/III , multicenter , randomize study include 420 patient six year + 3 year follow . 92 patient include phase II ; additional 328 patient include . Patients advance metastatic urothelial cancer impair renal function randomize one two follow chemotherapy arm : - Fractionated Cisplatin + Gemcitabine . - Carboplatin + Gemcitabine . The main objective part II study evaluate efficacy safety chemotherapy doublet platinum salt compound/Gemcitabine fractionate Cisplatin Carboplatin population . The main objective part III study compare efficacy term overall survival chemotherapy doublet platinum salt/Gemcitabine fractionate Cisplatin Carboplatin population .</brief_summary>
	<brief_title>A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine Treatment Advanced Metastatic Urothelial Cancer With Impaired Renal Function .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1. . Age &lt; = 18 year , patient age 75 year benefit geriatric assessment . 2. . Advanced metastatic urothelial cancer confirm histologically cytologically . 3. . Patients liable receive first line chemotherapy advance metastatic urothelial carcinoma . 4. . Measurable disease accord RECIST criterion V1.1 . 5. . Patients receive neoadjuvant adjuvant chemotherapy base platinum salt must complete treatment least 6 month enter study . 6. . Performance status &lt; = 2 . 7. . Life expectancy &gt; 3 month . 8. . Patients creatinine clearance 40 60 ml / min ( accord Cockcroft Gault ) . 9. . Patients contraindication overhydration . 10. . Satisfactory hematological test : Neutrophils &gt; 1.5 G / l Platelets &gt; 150 G / l , hemoglobin â‰¥ 10 g / dl . 11. . Satisfactory liver function test : total bilirubin &lt; 1.5 x ULN ( upper limit normal ) , AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) &lt; = 2.5 x ULN ( 5 x ULN liver metastasis ) . 12. . In case prior radiotherapy , minimum 14 day must relapse end radiotherapy study entry . 13. . For woman childbearing age , use effective contraceptive method study entry duration study 6 month last dose study treatment ; For sexually active fertile men partner childbearing age use effective contraception duration study 6 month last dose study treatment . 14. . Patient affiliate social security system France . 15. . Patient sign informed consent inclusion study specific procedure study . 1. . Any concomitant previous malignancy within 5 year prior study ( exception basal cell squamous cell carcinoma situ ) . 2. . Pregnant lactating woman . 3. . Patients brain metastasis meningeal symptom suggestive secondary location . 4. . Bisphosphonate Denosumab treatment initiate within 28 day prior randomization study patient start treatment study ( bisphosphonate denosumab treatment initiate within period longer 28 day randomization may continue without change study ) . 5. . Other concomitant cancer ( radiation therapy , radiopharmaceutical agent chemotherapy ) . 6. . Patients uncontrolled infection . 7. . Patients peripheral neuropathy grade &gt; 1 , whatever origin patient hearing loss . 8. . Patient unstable disease ( eg : unstable diabetes , poorly control hypertension , congestive heart failure myocardial infarction within 3 month prior study entry ) . 9. . Known hypersensitivity study drug . 10. . Treatment investigational drug within 30 day inclusion . 11. . Any psychological condition , familial , sociological geographical comply medical monitoring / procedure study protocol . 12. . Patient protect law .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Urothelial cancer , renal function impair .</keyword>
</DOC>